MA 15.11 CCNE1, PTGS2, TGFA and WISP2 Predict Benefit from Bevacizumab and Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer (SAKK19/09)

Sacha I. Rothschild(University Hospital of Basel), R. Jaggi(University of Bern), Sinisa Savic(University of Leeds), Daniel Rauch(Washington University in St. Louis), Miklos Pless(Ontario Institute for Cancer Research), Carsten Riether(University of Bern), Thilo Zander(Luzerner Kantonsspital), Adrian F. Ochsenbein(University of Bern), Martina Schneider(Valneva (Austria)), Martin Früh(University of Bern), Martin Brutsche(University of Basel), Q. Li(Swiss Group For Clinical Cancer Research), Richard Cathomas(Kantonsspital Graubünden), Christine Biaggi(Swiss Group For Clinical Cancer Research), Alfred Zippelius(University of Basel), Oliver Gautschi(Université Toulouse III - Paul Sabatier), Matthias Amrein(University of Bern), R. Stahel, Lukas Bubendorf(University of Basel), Norah H. Schuster(University of Bern), Daniel Betticher
Journal of Thoracic Oncology
November 1, 2017
10.1016/j.jtho.2017.09.592
Cited by 1

Related Papers

Tissue microarrays for high-throughput molecular profiling of tumor specimens
|Nature Medicine|1998|4.1k
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2019|3.4k
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
|Journal of Clinical Oncology|2004|2.4k
European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines
|European Urology|2020|2.2k
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
|The Lancet|2015|2k